Smruthi Organics Ltd - Stock Valuation and Financial Performance

BSE: 540686 | NSE: | Pharmaceuticals & Drugs | Small Cap

Smruthi Organics Share Price

123 -0.50 -0.40%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Smruthi Organics

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Smruthi Organics stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
140.8 Cr.
52-wk low:
112.7
52-wk high:
218.8

Is Smruthi Organics Ltd an attractive stock to invest in?

1. Is Smruthi Organics Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Smruthi Organics Ltd is a average quality company.

2. Is Smruthi Organics Ltd undervalued or overvalued?

The key valuation ratios of Smruthi Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Smruthi Organics Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Smruthi Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Smruthi Organics:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Smruthi Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % -0%9.5%10.6%-1%21.5%25%39.1%21%7.4%8.2%-
Value Creation
Index
-1.0-0.3-0.2-1.10.50.81.80.5-0.5-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 76.673.879.497.3137131127133141128120
Sales YoY Gr.--3.6%7.6%22.7%41.2%-4.6%-3.5%5.4%5.8%-9.5%-
Adj EPS -3.40.61.4-2.865.314.99.23.73.3-0.8
YoY Gr.-NA126.2%-303.6%NA-12.3%183.5%-38%-60.1%-11.9%-
BVPS (₹) 25.726.828.225.431.837.152.958.759.660.859.2
Adj Net
Profit
-3.80.71.6-3.26.9617.110.64.23.7-1
Cash Flow from Ops. 8.5149.25.112.121.422.82.212.14.4-
Debt/CF from Ops. 5.22.63.562.30.70.41.30.52.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.8%-1.5%0.3%-9.5%
Adj EPS NA-11.5%-39.8%-11.9%
BVPS10%13.9%4.8%2.1%
Share Price - 25.4% -21.2% -24.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-11.92.35-10.52115.333.116.66.25.4-1.3
Op. Profit
Mgn %
6.114.412.63.412.512.122.61479.55.2
Net Profit
Mgn %
-512-3.354.613.57.932.9-0.8
Debt to
Equity
1.51.211.10.80.40.200.10.20.1
Working Cap
Days
33431725819415516313913215319789
Cash Conv.
Cycle
9399908066584881929942

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 0.30%

Sales growth is not so good in last 4 quarters at -10.29%

Latest Financials - Smruthi Organics Ltd.

Standalone Consolidated
TTM EPS (₹) -0.8 -
TTM Sales (₹ Cr.) 120 -
BVPS (₹.) 59.2 -
Reserves (₹ Cr.) 58 -
P/BV 2.08 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 112.70 / 218.80
All Time Low / High (₹) 21.70 / 419.35
Market Cap (₹ Cr.) 141
Equity (₹ Cr.) 11.5
Face Value (₹) 10
Industry PE 44.3

Management X-Ray of Smruthi Organics:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Smruthi Organics

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales77747997137131127133141128
Operating Expenses 7263699412111698115131116
Manufacturing Costs78911131412161819
Material Costs53434961918366809172
Employee Cost 6789131412141617
Other Costs 55313458567
Operating Profit 511103171529181012
Operating Profit Margin (%) 6.1%14.4%12.5%3.3%12.1%11.6%22.6%13.8%6.9%9.4%
Other Income 0010141100
Interest 6544431111
Depreciation 5444444456
Exceptional Items 0000000000
Profit Before Tax -623-51012241445
Tax -211-1347301
Profit After Tax -412-378171044
PAT Margin (%) -5.0%1.0%2.0%-3.3%5.0%6.4%13.5%7.8%2.9%2.8%
Adjusted EPS (₹)-3.30.61.4-2.86.07.415.09.13.63.1
Dividend Payout Ratio (%)0%0%0%0%11%14%20%33%55%48%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 29313229364260676870
Share Capital 44444411111111
Reserves 26272825333949565758
Minority Interest0000000000
Debt403127292816103510
Long Term Debt171486221016
Short Term Debt23171923251410354
Trade Payables15151722302214112529
Others Liabilities 22261047777911
Total Liabilities 1071028584101889288107119

Fixed Assets

Gross Block8788309498104107114122131
Accumulated Depreciation5256064687276818591
Net Fixed Assets35323030303231333740
CWIP 1111201121
Investments 0000000000
Inventories18191921231718202430
Trade Receivables22192125362521283741
Cash Equivalents 22224416121
Others Assets30291256114456
Total Assets 1071028584101889288107119

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 914951221232124
PBT -623-51012241455
Adjustment 10877774556
Changes in Working Capital 44-13-550-133-6
Tax Paid 00000-3-6-4-1-1
Cash Flow From Investing Activity -100-3-4-5-37-10-7
Capex -1-1-2-4-5-5-4-7-9-8
Net Investments 000000013-11
Others 0111001100
Cash Flow From Financing Activity -8-14-9-2-5-17-7-12-23
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 4-4-4-2-400016
Interest Paid -6-5-4-4-4-3-1-1-1-1
Dividend Paid 00000-20-3-3-2
Others -6-5042-12-5-72-1
Net Cash Flow -10002-113-300
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-11.832.415.03-10.4820.9721.4333.2316.276.115.21
ROCE (%)-0.019.5310.6-0.9621.542539.08217.398.22
Asset Turnover Ratio0.70.750.911.161.491.391.411.491.461.17
PAT to CFO Conversion(x)N/A144.5N/A1.712.631.350.231
Working Capital Days
Receivable Days1069586868285666884108
Inventory Days94868375585551525774
Payable Days134130117114104114995771134

Smruthi Organics Ltd Stock News

Smruthi Organics Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Smruthi Organics on 20-Dec-2024 16:59 is ₹123.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Smruthi Organics stood at ₹140.8.
The latest P/E ratio of Smruthi Organics as of 20-Dec-2024 16:59 is 0.00.
The latest P/B ratio of Smruthi Organics as of 20-Dec-2024 16:59 is 2.08.
The 52-week high of Smruthi Organics is ₹218.8 and the 52-week low is ₹112.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Smruthi Organics is ₹119.8 ( Cr.) .

About Smruthi Organics Ltd

Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products. 

Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following: 
  • Process Development
  • Process Optimization
  • Process Validation
  • Analytical Methods Validation
  • Regulatory Support and DMF Registrations
  • Commercial Manufacturing

Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.

Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.

Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.

Product range of the company includes:

API   
  • Amlodipine Base
  • Amlodipine Besilate
  • Carbidopa
  • Carvedilol
  • Chlorhexidine Base
  • Chlorhexidine Salts
  • Ciprofloxacin HCI
  • Clofibrate
  • Diloxanide Furoate
  • Enrofloxacin
  • Fenofibrate
  • Fluconazole
  • Iopomidol
  • Metformin HCI
  • Norfloxacin
  • Pefloxacin
  • S-Amlodipine
  • Nabumetone
Drug Intermediate
  • Nabumetone
  • Iopamidol / Iohexol
  • Montelukast
  • Iopamidol
  • Co-enzyme Q10
  • Atorvastatin
  • Carvedilol
  • Ciprofloxacin/Enrofloxacin
  • Perindopril
Achievements/ recognition:
  • The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000. 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.